Genmab Stock Nasdaq Copenhagen
Equities
DK0010272202
Biotechnology & Medical Research
Sales 2024 * | 19.66B 2.8B | Sales 2025 * | 23.53B 3.36B | Capitalization | 130B 18.49B |
---|---|---|---|---|---|
Net income 2024 * | 5.11B 729M | Net income 2025 * | 6.8B 969M | EV / Sales 2024 * | 5.2 x |
Net cash position 2024 * | 27.32B 3.9B | Net cash position 2025 * | 34.49B 4.92B | EV / Sales 2025 * | 4.04 x |
P/E ratio 2024 * |
25.3
x | P/E ratio 2025 * |
19.4
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.87% |
Latest transcript on Genmab
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 63 | 98-12-31 | |
Anthony Pagano
DFI | Director of Finance/CFO | 46 | 06-12-31 |
Anthony Mancini
COO | Chief Operating Officer | 53 | 20-03-22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Deirdre Connelly
CHM | Chairman | 63 | 16-12-31 |
Anders Pedersen
BRD | Director/Board Member | 73 | 03-10-31 |
Rolf K. Hoffmann
BRD | Director/Board Member | 63 | 15-12-31 |
1st Jan change | Capi. | |
---|---|---|
-3.30% | 102B | |
+1.79% | 96.84B | |
-0.44% | 21.48B | |
-18.35% | 20.82B | |
-40.31% | 16.81B | |
-26.84% | 13.78B | |
+0.59% | 13.4B | |
+20.86% | 11.06B | |
-21.69% | 8.88B |